FOXO Technologies Inc. is a biotechnology company. The Company is focused on commercializing longevity science through products and services that serve the life insurance industry. Its epigenetic technology applies artificial intelligence (AI) to deoxyribonucleic acid (DNA) methylation to identify molecular biomarkers of human health and aging. The Company operates through two segments: FOXO Labs and FOXO Life. FOXO Labs is commercializing epigenetic biomarker technology to be used for mortality underwriting and risk classification in the global life insurance industry. Its biomarker technology enables the adoption of new saliva-based health and wellness biomarker solutions for underwriting and risk assessment. FOXO Life is redefining the relationship between consumers and insurers by combining life insurance with healthy longevity. FOXO Life seeks to transform the value proposition of the life insurance carrier from a provider of mortality risk protection products.
